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An understanding of the cost components of cancer care has led to a 
shift in treatment to the ambulatory setting, the development of care 
maps and algorithms to expedite diagnostic workup, a commitment by 
government to diagnostic assessment units and programs and increased 
use of home based palliative care (8,9).
The microsimulation model also enabled the evaluation of the 
cost-effectiveness of chemotherapy treatments, such as vinorelbine, 
gemcitibine, vinorelbine-cisplatin, taxol-carboplatin, all of which 
were demonstrated to be cost-effective in the POHEM model with 
vinorelbine-cisplatin being a dominant strategy when administered in 
the ambulatory setting (10). The important inﬂuence of the health care 
environment on the outcome of an economic analysis was demonstrat-
ed by a pharmacoeconomic analysis based on US Medicare reimburse-
ment ﬁgures which showed that vinorelbine cisplatin was actually 7% 
more costly in the USA than the paclitaxel - carboplatin due to lower 
administration costs and less frequent adverse events to manage (11)
As many of the chemotherapy regimens for advanced NSCLC produce 
similar survival outcomes, there are now numerous cost minimization 
studies in the literature from different countries which give insight into 
the least expensive chemotherapy regimen for that country’s health 
system.
The cost-effectiveness of second-line docetaxel has been evaluated by 
both Leighl et al (12) in the Canadian system and Holmes et al (13) in 
the United Kingdom. Both studies suggest that second-line therapy is 
cost-effective at $31,776 per LYG Canada and 13,863 pounds/LYG in 
the UK.
Recently, adjuvant chemotherapy for completely resected stage IB and 
II has been conﬁrmed to improve 5-year survival substantially (14). An 
economic analysis of the NCIC trial JBR10 demonstrated mean costs 
of treatment per patient in the observation and adjuvant chemotherapy 
arms of $CAD 23,878 and $31,319 respectively, with an ICER of CAD 
$7,175/LYG discounted (95% CI - $3,463 to $41,565) and $10,096/
LYG undiscounted (95% CI - $819 to $55,651). This conﬁrms adjuvant 
vinorelbine - cisplatin as a highly cost-effective treatment. It is impor-
tant to recognize that these cost-effective therapies can, nonetheless, 
add hugely to the economic burden of health care in countries because 
of the high average cost of treatment and the high incidence of the 
disease (19).
Because economic factors are playing a larger role in decision-making 
by funders, there has been a sharp increase in the number of economic 
analyses reported. From 1990-1999 inclusive, 181 publications related 
to lung neoplasms and cost/cost analyses were identiﬁed in a Medline 
search. Since 2000, 313 publications have been indexed. Many involve 
non-treatment cost-effectiveness analyses for screening, diagnosis and 
staging (PET), follow-up post surgery (CT) supportive care (darbepoi-
etin for anemia; GCSF for infections), as well as for thoracic surgery 
organizational design and CHART radiotherapy.
The increased volume of economic and pharmacoeconomic literature 
brings with it some challenges. Methodologies are often unclear with 
cost-minimization analyses being presented as cost-effectiveness analy-
ses or comparator therapies chosen that are non-standard. As well, not all 
analyses use the same measure of effectiveness. Cost per response or cost 
per progression free month are difﬁcult to interpret and/or to compare.
It is advised that lung oncologists familiarize themselves with econom-
ic evaluation methodologies as this literature will continue to grow and 
will increasingly inform decisions for the care of lung cancer patients. 
It is also advised that readers be wary of published studies that use 
atypical methods, comparators or measures of effectiveness.
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Organisation of services improves outcomes for patients with lung 
cancer
Gregor, Anna Erridge, Sara 
University of Edinburgh, Edinburgh, UK
Improvements in health outcomes can be due to introduction of new 
and more effective treatments, implementation of prevention strate-
gies, screening, earlier diagnosis or the consistent delivery of evidence 
based care. Estimates suggest that optimal delivery of care could be 
responsible for up to 40% of the potential gain and is fundamental for 
realisation of all other beneﬁts. 
For patients with lung cancer optimal organisation of care is essential 
to address their complex and changing needs and to provide appropriate 
support during their often short and difﬁcult disease journey. 
The fundamental principles are:
• Consistent and equitable access to evidence based care of deﬁned 
quality
• Ready access to information about care and outcomes
• Access to a multi-disciplinary team for decisions about management 
• Continuity of care through identiﬁed and accessible key healthcare 
workers
• Access to active and relevant research programme 
Copyright © 2007 by the International Association for the Study of Lung Cancer S211
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
• Provision of easily accessible palliative care 
• Access to support for patients and carers
These aims are delivered by care networks and assessed by prospective 
continuous audit of key outcome measures. 
Lung cancer in Scotland has had poor and unchanging 1outcomes 
ascribed to low and uneven access to optimal care2. The variable 
experience and suboptimal care provided for patients with lung cancer 
in Scotland was further highlighted during a national programme of 
standard setting and peer review organised by the Clinical Standards 
Board for Scotland.3 During a period spanning 2000/1 every hospital 
providing lung cancer care was assessed by submitting a self report on 
deﬁned number of service standards and subsequent external review 
which included patients and carers. 
We describe the process of reorganisation of lung cancer services 
in Scotland over the last twelve years and its effects on outcomes for 
patients with lung cancer.
In 2001, Scotland launched a comprehensive national cancer 
strategy4, which radically changed the way that all cancer services 
are planned and delivered. The beneﬁts of this reorganisation that are 
relevant to lung cancer include:
• formation of multidisciplinary disease speciﬁc networks serving a 
deﬁned population area and working across organisational boundaries 
• access to multi-disciplinary decision making
• establishment of prospective audit measuring and reporting com-
prehensive service performance against national standards based on 
evidence based guidelines (SIGN)
This national program of reform was supported by about $500 million 
of additional targeted investment providing:
• improvements in diagnostic facilities particularly increased CT scan-
ning capacity
• improved access to modern radiotherapy with replacement of old 
equipment and expansion of existing capacity and access to 3D 
conformal treatment 
• improved access to new drugs through a national programme of 
review and regional implementation
• national PET programme 
• cancer trials network that has led to 13% of all Scottish cancer 
patients participating in clinical trials. 
• appointment of additional staff
Impact of these changes is seen in comparison of lung cancer patients 
cohorts within deﬁned geographical area served by one cancer network 
(www.scan.scot.nhs.uk) and participating in prospective audit with 
>90% capture and 98% accuracy.
Comparison of treatment intent and delivery
1995, N=927 2002, N=971 2004, N=939 Chi squared
Any treatment 582 (63%) 605 (62%) 568 (60%) P=0.85
Potentially curative 131 (14%) 229 (24%) 230 (25%) P<0.001
 Palliative 451 (49%) 376 (39%) 338 (35%)
Surgery 95 (10.2%) 102 (10.5%) 91 (9.7%) P=0.88
Radiotherapy 400 (43%) 433 (45%) 378 (40%) P=0.55
Radical1 44 (4.7%) 146 (15%) 149 (16%) P<0.001
 Palliative 356 (38%) 296 (31%) 229 (24%)
Chemotherapy 151 (16%) 196 (20%) 249 (27%) 249 (27%)
 
Survival comparison
Median 1 year 2 year
1995 N=927 4.1(3.5-4.6) 23.4% (20.7-26.1) 11.4% (9.3-13.5)
2002N=971 5.1 (4.5-5.8) 28.9% (26.1-31.8) 14.8% (12.5-17.1)
Log rank p=0.0029,
In addition to the hard endpoints of treatment and survival these 
reforms have radically improved qualitative measures such as access to 
information, Clinical Nurse Specialists and symptom management.
One remaining question is why do 1 in 3 Scottish cancer patients still 
do not receive any anti-cancer therapy? It may be appropriate in elderly 
population with high levels of co-morbidity, but further prospective 
population based studies of the decision making process are required.
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Decision-making of lung cancer patients and family
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Sometimes it is not easy to decide whether to treat or not in lung cancer 
patients (1). Among patients who died of lung cancer, signiﬁcant pro-
portions were found to have received chemotherapy up to the end-of-
life and to have visited ERs. Palliative care and hospice referrals were 
not conducted well during the end-of-life period (2). 
Palliative Chemotherapy:
Among patients who died of cancer, chemotherapy was used frequently 
in the last 3 months of life. The cancer’s responsiveness to chemothera-
py does not seem to inﬂuence whether dying patients receive chemo-
therapy at the end of life (3).
In our study, newly diagnosed chemo-naïve patients with advanced or 
recurrent NSCLC (n= 404) were evaluated. All patients were histologi-
cally or pathologically proven to be NSCLC, with performance status 
0 to 2. All patients received platinum-based combination chemotherapy 
as the ﬁrst-line treatment. The old age group was deﬁned as patients 
with 65 years or more of age. The average number of total regimens 
(2.31 of old age vs. 2.81 of young age, respectively; p<0.001) and 
cycles (8.78 vs. 10.69, p=0.006) per head were signiﬁcantly less in the 
old age group than in the young age group. 
Multi-center study in Korea showed that 48.7 % of cancer patients in 
the last 6 months of life, 43.9% in the last 3 months, and 30.9% in the 
last month of life received chemotherapy in Korea. The frequency of 
chemotherapy use was lower for older patients (P for trend < 0.001). In 
those older than 65 years, there was no difference between women and 
men in the proportion that received chemotherapy. For patients < 65 
years of age, however, a larger proportion of women than men received 
chemotherapy, and chemotherapy use was signiﬁcantly less frequent for 
patients with refractory disease than for those with responsive disease. 
This difference, however, was lower for patients older than 65 years of 
age. Patients dying at a relatively small hospital without a hospice inpa-
tient unit were signiﬁcantly more likely to receive chemotherapy than 
patients at a larger, hospice-containing hospital, as were patients with 
